GSM5359419
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.450
- P53_PATHWAY+0.340
- PANCREAS_BETA_CELLS+0.310
- PROTEIN_SECRETION+0.290
- HYPOXIA+0.280
- PEROXISOME+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- FATTY_ACID_METABOLISM+0.260
- XENOBIOTIC_METABOLISM+0.260
- ADIPOGENESIS+0.230
Top 10 suppressed
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.490
- ALLOGRAFT_REJECTION-0.370
- MYC_TARGETS_V2-0.270
- INFLAMMATORY_RESPONSE-0.260
- MITOTIC_SPINDLE-0.260
- HEDGEHOG_SIGNALING-0.210
- MYC_TARGETS_V1-0.200
- IL6_JAK_STAT3_SIGNALING-0.190
- NOTCH_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 367ce5cb-52f9-4c87-aaa3-2808fca08bef | — | — | 0.798 |
| 2 | TCGA-69-8253-01A-11R-2287-07 | — | cohortA2 | 0.705 |
| 3 | TCGA-44-7671-01A-11R-2066-07 | — | cohortA2 | 0.703 |
| 4 | TCGA-73-4677-01A-01R-1206-07 | — | cohortA2 | 0.701 |
| 5 | MNG1099 | — | — | 0.686 |
| 6 | SRR8518177 | — | F | 0.681 |
| 7 | SRR6079992 | — | — | 0.670 |
| 8 | e94b6daf-3aed-4496-b64b-1b1a7d8e2011 | — | — | 0.668 |
| 9 | MNG1112 | — | — | 0.664 |
| 10 | SRR8943013 | — | — | 0.662 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |